Thirty five novel nsSNPs may effect on *ADAMTS13* protein leading to Thrombotic thrombocytopenic purpura (TTP) using bioinformatics approach

Tebyan A. Abdelhameed^{*1}, Arwa I. Ahmed^{*1}, Mujahed I. Mustafa¹, Amel N. Eltayeb¹, Fatima A. Abdelrhman¹, Amal B. Ahmed¹, Najla B. Ahmed¹, Hiba Y. Khadir¹, Adla M. Hassan¹, Huda K. Mohamed¹, Soada A. Osman¹, Mustafa Elhag¹, Mohamed A. Hassan¹.

1. Department of biotechnology, Africa City of Technology, Sudan.

*Authors contribution is equally.

Corresponding author: Tebyan A. Abdelhameed: tebyanameer2511@gmail.com.

ABSTRACT

Background: Genetic polymorphisms in the *ADAMTS13* gene are associated with thrombotic thrombocytopenic purpura or TTP, a life-threatening microangiopathic disorder. This study aims to predict the possible pathogenic SNPs of this gene and their impact on the protein structure and function using insilico methods.

Methods: SNPs retrieved from the NCBI database were analyzed using several bioinformatics tools. The different algorithms applied collectively to predict the effect of single nucleotide substitution on both structure and function of the *ADAMTS13* protein.

Results: Fifty one mutations were found to be highly damaging to the structure and function of the protein. Of those, thirty five were novel nsSNPs not previously reported in the literature.

Conclusion: According to our analysis we found thirty five nsSNPs effects on *ADAMTS13* protein leading to thrombotic thrombocytopenic purpura using computational approach. Bioinformatics tools are vital in prediction analysis, making use of increasingly voluminous biomedical data thereby providing markers for screening or for genetic mapping studies.

Keywords: *Thrombotic thrombocytopenic purpura (TTP), A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 (ADAMTS13), microangiopathic disorder, Bioinformatics, single nucleotide polymorphisms (SNPs), computational, insilico.*

INTRODUCTION

Thrombotic thrombocytopenic purpura (TTP), also known as Upshaw – Schulman syndrome (USS) is one of microangiopathic disorder which is a life threatening thrombotic microangiopathy [1-4], caused by widespread of microthrombi composed from highly reactive high molecular von Willebrand factor (vWF) and platelets due to deficiency of the vWF- cleaving metalloprotease encoded by *ADAMTS13* gene [1, 5, 6]. *ADAMTS13* (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), is highly specific multi-domain plasma reprotolysin-like metalloprotease [4, 7-9], located on chromosome 9 (9q34) [10], which is normally synthesized in the kidney (major site of production), liver and endothelium cells [11, 12]. The disease is characterized by thrombocytopenia, hemolytic anemia, neurologic signs, fever, organ ischemia and subsequently impaired function of different organs especially the kidneys and the central nervous system (CNS) [4, 5, 11, 13-16].

The congenital TTP is usually occurring due to mutations in *ADAMTS13*, while the acquired occur due to autoantibodies against *ADAMTS13* [11-13]. Several studies revealed that the single nucleotide polymorphisms may be associated with reduced *ADAMTS13* secretion and activity, and some mutations in *ADAMTS13* gene responsible from phenotype expression of TTP characteristics [2, 7, 10-13, 17-22]. Although there are some researchers studied the mutations in *ADAMTS13* [10, 12, 14, 16, 20, 21, 23] but the genetic mechanism of some mutations remain unclear. Our study aimed to define the impact of various SNPs in *ADAMTS13* gene using a bioinformatics approach and assessing the effect of these SNPs on the structure and function of *ADAMTS13* protein that may be implicated in the disease susceptibility. Recently, bioinformatics approach make huge differences in science through providing massive information about genes, proteins, domains, SNPs, and many more. It is valuable to know genes functions and their interaction with other genes so the pathways in normal and abnormal case, genetic evolution to know who is closest to whom, proteins function so the structure and properties and SNPs and its association with disorder which all poured in health line. This study is regarded as the first computational study to predict the effects of SNPs on *ADAMTS13* protein function and structure.

METHODS

Data mining

The data for human *ADAMTS13* gene were collected from the National Center for Biological Information (NCBI) website [24]. The SNP information (SNP ID) of the *ADAMTS13* gene was retrieved from the NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>) and the protein ID and its sequence was collected from Swiss-Prot databases with the accession number: (Q76LX8). (<http://expasy.org/>) [25].

SIFT

SIFT (Sorting Intolerant from Tolerant) is an online computational tool [26] to detect a harmful non-synonymous single-base nucleotide polymorphism (nsSNP). SIFT predicts whether an amino acid replacement affects protein function. SIFT prediction is based on the grade of conservation of amino acid residues in sequence alignments resulting from closely related sequences, collected through PSI-BLAST. SIFT can be applied to naturally occurring non-synonymous polymorphisms or laboratory induced missense mutations, the genetic

mutation that causes a single amino acid substitution (AAS) in a protein sequence subsequently changing the carrier's phenotype and health status. SIFT expects whether these substitutions affect protein function by using sequence homology, SIFT predicts the effects of all possible substitutions at each position in the protein sequence. Furthermore, the algorithm performs a comprehensive search in protein repositories to find the tolerance of each candidate compared to the conserved counterparts. Non-synonymous reference SNPs identity (nsSNPs ID) were downloaded from online dbSNPs of NCBI and then submitted to SIFT. Results are expressed as damaging (deleterious) or benign (Tolerated) depending on cutoff value 0.05; as values below or equal to (0.0-0.04) predicted to be damaging or intolerant while (0.05_1) is benign or tolerated, then the damaging SNPs were reanalyzed by Polyphen software which predicts the effect of mutations on both structural and functional sides. It is available at (<http://sift.bii.a-star.edu.sg/>).

Polyphen-2

Polyphen-2 is a software tool [27] used to predict the possible impact of an amino acid substitution on both structure and function of a human protein by analysis of multiple sequence alignment and protein 3D structure, in addition, it calculates position-specific independent count scores (PSIC) for each of two variants, and then calculates the (PSIC) scores difference between two variants. The higher a PSIC score difference, the higher the functional impact a particular amino acid substitution is expected to have. Prediction outcomes could be categorized as probably damaging, possibly damaging or benign according to the value of PSIC as it ranges from (0_1); values closer to zero considered benign while values closer to 1 considered probably damaging and also it can be indicated by a vertical black marker inside a color gradient bar, where green is benign and red is damaging, nsSNPs that predicted to be intolerant by Sift has been submitted to Polyphen as protein sequence in FASTA format that obtained from UniprotKB /ExPasy after submitting the relevant ensemble protein (ESNP) there, and then we entered position of mutation, native amino acid and the new substituent for both structural and functional predictions. PolyPhen version 2.2.2 is available at the website. (<http://genetics.bwh.harvard.edu/pph2/index.shtml>)

Provean

Provean is a software tool which predicts whether an amino acid substitution or indel has an impact on the biological function of a protein. It is useful for purifying sequence variants to identify nonsynonymous or indel variants that are predicted to be functionally important [28]. Variants with a score equal to or below -2.5 are considered "deleterious" while variants with a score above -2.5 are considered "neutral." It is available at (<https://roslab.org/services/snap2web/>).

SNAP2

Functional effects of mutations are predicted with SNAP2 [29]. SNAP2 is a trained classifier that is based on a machine learning device called "neural network". It distinguishes between effect and neutral variants/non-synonymous SNPs by taking a variety of sequence and variant features into account. The most important input signal for the prediction is the evolutionary information taken from an automatically generated multiple sequence alignment. Also, structural features such as predicted secondary structure and solvent accessibility are considered. If available also annotation (i.e. known functional residues, pattern, regions) of

the sequence or close homologs are pulled in. In a cross-validation over 100,000 experimentally annotated variants, SNAP2 reached sustained two-state accuracy (effect/neutral) of 82% (at an AUC of 0.9). In our hands, this constitutes an important and significant improvement over other methods. It is available at (<https://rostlab.org/services/snap2web/>).

PHD-SNP

PHD-SNP is an online Support Vector Machine (SVM) based classifier optimized to predict if a given single point protein mutation can be classified as disease-related or as a neutral polymorphism [30]. It is available at: (<http://http://snps.biofold.org/phd-snp/phdsnp.html>)

SNPs& Go:

SNPs&GO is an algorithm developed in the Laboratory of Biocomputing at the University of Bologna directed by Prof. Rita Casadio. SNPs&GO is an accurate method that, starting from a protein sequence, can predict whether a variation is disease related or not by exploiting the corresponding protein functional annotation. SNPs&GO collects in unique framework information derived from protein sequence, evolutionary information, and function as encoded in the Gene Ontology terms, and outperforms other available predictive methods [30]. It is available at (<http://snps.biofold.org/snps-and-go/snps-and-go.html>)

Pmut

PMUT a web-based tool for the annotation of pathological variants on proteins, allows the fast and accurate prediction (approximately 80% success rate in humans) of the pathological character of single point amino acidic mutations based on the use of neural networks [31]. It is available at (<http://mmb.irbbarcelona.org/PMut>).

I-Mutant 3.0

I-Mutant 3.0 Is a neural network based tool for the routine analysis of protein stability and alterations by taking into account the single-site mutations [32]. The FASTA sequence of protein retrieved from UniProt is used as an input to predict the mutational effect on protein stability. It is available at (<http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>).

Project Hope

Project hope (version 1.0 is an online webserver used to search protein 3D structures by collecting structural information from a series of sources, including calculations on the 3D protein structure (if available), sequence annotations in UniprotKB and predictions from DAS servers. Protein sequences were submitted to project hope server in order to analyze the structural and conformational variations that have resulted from single amino acid substitution corresponding to single nucleotide substitution. It is available at (<http://www.cmbi.ru.nl/hope>) [33].

UCSF (University of California at San Francisco) Chimera

UCSF Chimera (<https://www.cgl.ucsf.edu/chimera/>) is a highly extensible program for interactive visualization and analysis of molecular structures and related data, including density maps, supramolecular assemblies, sequence alignments, docking results, trajectories, and conformational ensembles. High-quality images and animations can be generated. Chimera includes complete documentation and several tutorials. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics (RBVI), supported in part by the National Institutes of Health (P41-GM103311) [34].

GeneMANIA

We submitted genes and selected from a list of data sets that they wish to query. GeneMANIA approach to know protein function prediction integrate multiple genomics and proteomics data sources to make inferences about the function of unknown proteins [35]. It is available at (<http://www.genemania.org/>).

RESULTS

***ADAMTS13* gene investigation using dbSNP/NCBI:**

This study identified the total number of nsSNP in Homo sapiens located in the coding region of *ADAMTS13* gene, were investigate in dbSNP/NCBI Database [24]. Out of 1291 SNPs there are 821 nsSNPs (missense mutations).

Functional analysis of *ADAMTS13* gene using SIFT, Polyphen-2, Provean, SNAP2, PHD-SNP, SNP&GO, PHD-SNP and P-Mut softwares:

821 nsSNPs (missense mutations) were submitted to SIFT server, PolyPhen-2 server, Provean sever and SNAP2 respectively, 323 SNPs were predicted to be deleterious in SIFT server. In PolyPhen-2 server, our result showed that 491 were found to be damaging (133 possibly damaging and 358 probably damaging showed deleterious). In Provean server our result showed that 393 SNPs were predicted to be deleterious. While in SNAP2 server our result showed that 418 SNPs were predicted to be Effect. The differences in prediction capabilities refer to the fact that every prediction algorithm uses different sets of sequences and alignments. In table (2) we have submitted four positive results which are 66 results from SIFT, PolyPhen-2, Provean and SNAP2 to observe the disease causing one by SNP&GO, PHD-SNP and P-Mut servers.

In SNP&GO, PHD-SNP and P-Mut softwares were used to predict the association of SNPs with the disease. According to SNP&GO, PHD-SNP and P-Mut (57, 66 and 57 SNPs respectively) were found to be disease related SNPs. We selected the triple disease related SNPs only in 3 softwares (51 SNPs) for further analysis by I-Mutant 3.0, Table (3).

Table (1): Damaging or Deleterious or effect nsSNPs associated variations predicted by various softwares:

Amino Acid Change	SIFT		Polyphen		PROVEAN		SNAP2	
	Prediction	Score	Prediction	Score	Score	Prediction	Prediction	Score
S207R	D	0	probably damaging	1	-4.694	Deleterious	Effect	72
C208S	D	0	probably damaging	1	-9.654	Deleterious	Effect	73
G215S	D	0	probably damaging	1	-5.792	Deleterious	Effect	39
H234Q	D	0	probably damaging	1	-7.412	Deleterious	Effect	64
D235Y	D	0	probably damaging	1	-8.077	Deleterious	Effect	74
S263Y	D	0	probably damaging	1	-5.39	Deleterious	Effect	56
P301R	D	0	probably damaging	1	-7.772	Deleterious	Effect	45
G302A	D	0	probably damaging	1	-5.447	Deleterious	Effect	34
C311Y	D	0	probably damaging	1	-10.612	Deleterious	Effect	73
L335P	D	0	probably damaging	1	-6.907	Deleterious	Effect	69
P353L	D	0	probably damaging	1	-9.201	Deleterious	Effect	43
W390C	D	0	probably damaging	1	-12.291	Deleterious	effect	65
R398C	D	0	probably damaging	1	-7.608	Deleterious	effect	74
R398H	D	0	probably damaging	1	-4.753	Deleterious	effect	97
G403V	D	0	probably damaging	1	-8.572	Deleterious	effect	44
R409W	D	0	probably damaging	1	-7.608	Deleterious	effect	82
C411Y	D	0	probably damaging	1	-10.457	Deleterious	effect	70
P416H	D	0	probably damaging	1	-8.281	Deleterious	effect	63
G419W	D	0	probably damaging	1	-7.569	Deleterious	effect	79
G419A	D	0	probably damaging	1	-5.662	Deleterious	effect	55
G419V	D	0	probably damaging	1	-8.506	Deleterious	effect	59
R421C	D	0	probably damaging	1	-5.298	Deleterious	effect	46
C423R	D	0	probably damaging	1	-11.441	Deleterious	effect	57
G425D	D	0	probably damaging	1	-6.674	Deleterious	effect	54
G425V	D	0	probably damaging	1	-8.581	Deleterious	effect	48
C450R	D	0	probably damaging	1	-11.856	Deleterious	effect	78
C483Y	D	0	probably damaging	1	-10.57	Deleterious	effect	53
D504N	D	0	probably damaging	1	-4.927	Deleterious	effect	47
T506N	D	0	probably damaging	1	-4.94	Deleterious	effect	50
C508Y	D	0	probably damaging	1	-9.405	Deleterious	effect	54
G525D	D	0	probably damaging	1	-6.89	Deleterious	effect	85
R660W	D	0	probably damaging	1	-4.945	Deleterious	effect	53
S696W	D	0	probably damaging	1	-5.135	Deleterious	effect	50
C699R	D	0	probably damaging	1	-10.987	Deleterious	effect	90
C758W	D	0	probably damaging	1	-8.165	Deleterious	effect	82
G759R	D	0	probably damaging	1	-5.59	Deleterious	effect	67
G759W	D	0	probably damaging	1	-5.693	Deleterious	effect	47
G761S	D	0	probably damaging	1	-4.454	Deleterious	effect	44
C864R	D	0	probably damaging	1	-8.616	Deleterious	effect	58
C908Y	D	0	probably damaging	1	-10.074	Deleterious	effect	82
C908S	D	0	probably damaging	1	-9.16	Deleterious	effect	77
G911V	D	0	probably damaging	1	-8.252	Deleterious	effect	60
C951G	D	0	probably damaging	1	-10.071	Deleterious	effect	95
R979W	D	0	probably damaging	1	-4.359	Deleterious	effect	82
C1024G	D	0	probably damaging	1	-11.055	Deleterious	effect	97
C1028R	D	0	probably damaging	1	-11.021	Deleterious	effect	85
C1028Y	D	0	probably damaging	1	-10.092	Deleterious	effect	85
G1031R	D	0	probably damaging	1	-7.22	Deleterious	effect	89
R1035C	D	0	probably damaging	1	-6.806	Deleterious	effect	80
C1039Y	D	0	probably damaging	1	-9.175	Deleterious	effect	71
C1192Y	D	0	probably damaging	1	-5.868	Deleterious	effect	74

Table (2): Disease effect nsSNPs associated variations predicted by various softwares:

Amino acid change	PHD		SNP & GO		P-MUT	
	Prediction	RI	Probability	Probability	RI	Prediction
S207R	Disease	6	0.819	Disease	2	0.596
C208S	Disease	7	0.852	Disease	6	0.819
G215S	Disease	7	0.844	Disease	6	0.813
H234Q	Disease	6	0.819	Disease	7	0.833
D235Y	Disease	9	0.928	Disease	8	0.903
S263Y	Disease	3	0.659	Disease	5	0.743
P301R	Disease	5	0.773	Disease	1	0.552
G302A	Disease	4	0.693	Disease	5	0.761

C311Y	Disease	9	0.964	Disease	8	0.897	0.79 (89%)	Disease
L335P	Disease	7	0.828	Disease	6	0.799	0.80 (89%)	Disease
P353L	Disease	4	0.711	Disease	1	0.528	0.74 (87%)	Disease
W390C	Disease	5	0.75	Disease	5	0.751	0.83 (90%)	Disease
R398C	Disease	7	0.861	Disease	5	0.738	0.82 (90%)	Disease
R398H	Disease	5	0.747	Disease	2	0.592	0.75 (87%)	Disease
G403V	Disease	6	0.823	Disease	5	0.738	0.79 (89%)	Disease
R409W	Disease	9	0.926	Disease	7	0.859	0.69 (86%)	Disease
C411Y	Disease	9	0.945	Disease	7	0.867	0.79 (89%)	Disease
P416H	Disease	6	0.8	Disease	1	0.54	0.83 (90%)	Disease
G419W	Disease	8	0.896	Disease	6	0.808	0.79 (89%)	Disease
G419A	Disease	6	0.78	Disease	2	0.608	0.56 (81%)	Disease
G419V	Disease	8	0.885	Disease	5	0.77	0.73 (87%)	Disease
R421C	Disease	7	0.854	Disease	6	0.809	0.72 (87%)	Disease
C423R	Disease	9	0.928	Disease	8	0.887	0.79 (89%)	Disease
G425D	Disease	8	0.923	Disease	7	0.86	0.74 (87%)	Disease
G425V	Disease	8	0.919	Disease	7	0.862	0.79 (89%)	Disease
C450R	Disease	8	0.894	Disease	7	0.837	0.79 (89%)	Disease
C483Y	Disease	9	0.956	Disease	8	0.902	0.79 (89%)	Disease
D504N	Disease	7	0.834	Disease	6	0.819	0.73 (87%)	Disease
T506N	Disease	5	0.761	Disease	5	0.763	0.74 (87%)	Disease
C508Y	Disease	8	0.886	Disease	7	0.85	0.79 (89%)	Disease
G525D	Disease	8	0.876	Disease	7	0.838	0.75 (88%)	Disease
R660W	Disease	5	0.771	Disease	7	0.842	0.53 (80%)	Disease
S696W	Disease	6	0.822	Disease	4	0.704	0.83 (90%)	Disease
C699R	Disease	9	0.927	Disease	7	0.875	0.76 (88%)	Disease
C758W	Disease	8	0.9	Disease	7	0.863	0.60 (82%)	Disease
G759R	Disease	5	0.763	Disease	3	0.657	0.59 (82%)	Disease
G759W	Disease	7	0.833	Disease	5	0.748	0.71 (86%)	Disease
G761S	Disease	6	0.795	Disease	3	0.628	0.67 (85%)	Disease
C864R	Disease	7	0.844	Disease	3	0.632	0.65 (84%)	Disease
C908Y	Disease	9	0.937	Disease	7	0.864	0.83 (90%)	Disease
C908S	Disease	8	0.9	Disease	6	0.821	0.83 (90%)	Disease
G911V	Disease	8	0.884	Disease	5	0.738	0.83 (90%)	Disease
C951G	Disease	8	0.894	Disease	1	0.556	0.78 (88%)	Disease
R979W	Disease	6	0.799	Disease	2	0.578	0.69 (86%)	Disease
C1024G	Disease	8	0.884	Disease	5	0.736	0.85 (91%)	Disease
C1028R	Disease	8	0.879	Disease	6	0.797	0.85 (91%)	Disease
C1028Y	Disease	8	0.91	Disease	6	0.8	0.85 (91%)	Disease
G1031R	Disease	6	0.779	Disease	3	0.657	0.76 (88%)	Disease
R1035C	Disease	9	0.927	Disease	2	0.615	0.83 (90%)	Disease
C1039Y	Disease	9	0.95	Disease	7	0.85	0.76 (88%)	Disease
C1192Y	Disease	7	0.827	Disease	0	0.512	0.55 (81%)	Disease

Prediction of Change in Stability due to Mutation Using I-Mutant 3.0 Server

I-Mutant result revealed that the protein stability decreased which destabilize the amino acid interaction (46). While five were found to be increased the protein stability (Table 3).

Table (3): stability analysis predicted by I-Mutant version 3.0:

Substitution	I-Mutant Prediction	I-Mutant Score	I-Mutant RI
S207R	Decrease	0.08	0
C208S	Decrease	-0.58	3
G215S	Decrease	-1.11	8
H234Q	Decrease	-0.21	3
D235Y	Increase	-0.12	6
S263Y	Increase	0.11	4
P301R	Decrease	-0.83	5
G302A	Decrease	-0.39	1
C311Y	Decrease	-0.32	3
L335P	Decrease	-1.46	2
P353L	Decrease	-0.77	7
W390C	Decrease	-1.3	8
R398C	Decrease	-0.99	3
R398H	Decrease	-1.17	7
G403V	Decrease	-0.61	6
R409W	Decrease	-0.44	4
C411Y	Decrease	-0.35	3
P416H	Decrease	-1.26	9
G419W	Decrease	-0.25	4
G419A	Decrease	-0.61	6
G419V	Decrease	-0.53	6

R421C	Decrease	-0.73	4
C423R	Increase	-0.26	0
G425D	Decrease	-0.91	7
G425V	Decrease	-0.38	5
C450R	Increase	0.02	2
C483Y	Decrease	-0.98	1
D504N	Decrease	-1.25	5
T506N	Decrease	-1.01	3
C508Y	Decrease	-0.37	1
G525D	Decrease	-0.79	4
R660W	Decrease	-0.26	4
S696W	Increase	0	3
C699R	Decrease	-0.55	5
C758W	Decrease	-0.19	3
G759R	Decrease	-0.46	4
G759W	Decrease	-0.28	2
G761S	Decrease	-0.89	5
C864R	Decrease	-0.13	0
C908Y	Decrease	-0.4	3
C908S	Decrease	-0.86	8
G911V	Decrease	-17	1
C951G	Decrease	-0.98	5
R979W	Decrease	-0.38	6
C1024G	Decrease	-1.39	9
C1028R	Decrease	-0.52	6
C1028Y	Decrease	-0.38	3
G1031R	Decrease	-0.54	6
R1035C	Decrease	-0.73	5
C1039Y	Decrease	-0.11	3
C1192Y	Decrease	-0.13	0

Modeling of amino acid substitution effects on protein structure using Chimera

Figure (1): (S207R): change in the amino Serine (green box) into an Arginine (redbox) at position 207.

Figure (2): (C208S): change in the amino Cysteine (greenbox) into a Serine (red box) at position 208.

Figure (3): (G215S): change in the amino Glycine (green box) into a Serine (redbox) at position 215.

Figure (4): (H234Q): change in the amino Histidine (green box) into a Glutamine (red box) at position 234.

Figure (5): (D235Y): change in the amino Aspartic Acid (green box) into a Tyrosine (red box) at position 235.

Figure (6): (S263Y): change in the amino Serine (green box) into a Tyrosine (red box) at position 263.

Figure (7): (P301R) change in the amino Proline (green box) into an Arginine (red box) at position 301.

Figure (8): (G302A): change in the amino Glycine (green box) into an Alanine (red box) at position 302.

Figure (9): (C311Y): change in the amino Cysteine (green box) into a Tyrosine (red box) at position 311.

Figure (10): (L335P): change in the amino acid Leucine (green box) into Proline (red box) at position 335.

Figure (11): (P353L): change in the amino acid Proline (green box) into Leucine (red box) at position 353.

Figure (12): (W390C): change in the amino acid Tryptophan (green box) into Cysteine (red box) at position 390

Figure (13): (R398C): change in the amino acid Arginine (green box) into Cysteine (red box) at position 398.

Figure (14): (R398H): change in the amino acid Arginine (green box) into Histidine (red box) at position 398.

Figure (15): (G403V): change in the amino acid Glycine (green box) into Valine (red box) at position 403.

Figure (16): (R409W): change in the amino acid Arginine (green box) into Tryptophan (red box) at position 409.

Figure (17): (C411Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 411.

Figure (18): (P416H): change in the amino acid Proline (green box) into Histidine (red box) at position 416.

Figure (19): (G419W): change in the amino acid Glycine (green box) into Tryptophan (red box) at position 419.

Figure (20): (G419A): change in the amino acid Glycine (green box) into Alanine (red box) at position 419.

Figure (21): (G419V): change in the amino acid Glycine (green box) into Valine (red box) at position 419.

Figure (22): (R421C): change in the amino acid Arginine (green box) into Cysteine (red box) at position 421.

Figure (23): (C423R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 423.

Figure (24): (G425D): change in the amino acid Glycine (green box) into Aspartic Acid (red box) at position 425.

Figure (25): (G425V): change in the amino acid Glycine (green box) into Valine (red box) at position 425.

Figure (26): (C450R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 450.

Figure (27): (C483Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 483.

Figure (28): (D504N): change in the amino acid Aspartic Acid (green box) into Asparagine (red box) at position 504.

Figure (29): (T506N): change in the amino acid Threonine (green box) into Asparagine (red box) at position 506.

Figure (30): (C508Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 508.

Figure (31): (G525D): change in the amino acid Glycine (green box) into Aspartic Acid (red box) at position 525.

Figure (32): (R660W): change in the amino acid Arginine (green box) into Tryptophan (red box) at position 660.

Figure (33): (S696W): change in the amino acid Serine (green box) into Tryptophan (red box) at position 696.

Figure (34): (C699R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 699.

Figure (35): (C758W): change in the amino acid Cysteine (green box) into Tryptophan (red box) at position 758.

Figure (36): (G759R): change in the amino acid Glycine (green box) into Tryptophan (red box) at position 759.

Figure (37): (G759W): change in the amino acid Glycine (green box) into Tryptophan (red box) at position 759.

Figure (38): (G761S): change in the amino acid Glycine (green box) into Serine (red box) at position 761.

Figure (39): (C864R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 864.

Figure (40): (C908Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 908.

Figure (41): (C908S): change in the amino acid Cysteine (green box) into Serine (red box) at position 908.

Figure (42): (G911V): change in the amino acid Glycine (green box) into Valine (red box) at position 911.

Figure (43): (C951G): change in the amino acid Cysteine (green box) into Glycine (red box) at position 951.

Figure (44): (R979W): change in the amino acid Arginine (green box) into Tryptophan (red box) at position 979.

Figure (45): (C1024G): change in the amino acid Cysteine (green box) into Glycine (red box) at position 1024.

Figure (46): (C1028R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 1028.

Figure (47): (C1028Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 1028.

Figure (48): (G1031R): change in the amino acid Glycine (green box) into Arginine (red box) at position 1031.

Figure (49): (R1035C): change in the amino acid Arginine (green box) into Cysteine (red box) at position 1035.

Figure (50): (C1039Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 1039.

Figure (51): (C1192Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 1192.

Interactions of *ADAMTS13* gene with other Functional Genes illustrated by GeneMANIA

GeneMANIA revealed that *ADAMTS13* has this function: metallopeptidase activity. The genes co-expressed with, share similar protein domain, or participate to achieve similar function are illustrated by GeneMANIA and shown in figure (52) Table (4) and (5).

Table (4): The *ADAMTS13* gene functions and its appearance in network and genome:

Function	FDR	Genes in network	Genes in genome
metal ion transmembrane transporter activity	0.813275	4	238
inorganic cation transmembrane transporter activity	0.813275	4	266
metallopeptidase activity	0.813275	3	80
blood coagulation, intrinsic pathway	0.813275	2	18
blood coagulation, fibrin clot formation	0.890003	2	21

***FDR:** false discovery rate is greater than or equal to the probability that this is a false positive.

Table (5): The gene co-expressed, share domain and Interaction with *ADAMTS13* gene network

Gene 1	Gene 2	Weight	Network group	Network
KCNC4	F8	0.008013	Co-expression	Wang-Maris-2006
ANGPTL6	ADAMTS13	0.011534	Co-expression	Mallon-McKay-2013
TRPV1	ADAMTS13	0.016478	Co-expression	Mallon-McKay-2013
POFUT2	ADAMTS13	0.024919	Co-expression	Mallon-McKay-2013
C2orf72	ADAMTS13	0.024335	Co-expression	Mallon-McKay-2013
KCNC4	ADAMTS13	0.021195	Co-expression	Mallon-McKay-2013
MSI1	ADAMTS13	0.021491	Co-expression	Mallon-McKay-2013
MSI1	CACNG4	0.016442	Co-expression	Mallon-McKay-2013
KCNK17	ANGPTL6	0.011594	Co-expression	Mallon-McKay-2013
CACNG4	ADAMTS13	0.018641	Co-expression	Dobbin-Giordano-2005
GK2	ADAMTS13	0.014198	Co-expression	Dobbin-Giordano-2005
TAS2R7	ADAMTS13	0.018503	Co-expression	Dobbin-Giordano-2005
ADAMTS6	ADAMTS13	0.010844	Co-expression	Dobbin-Giordano-2005
SLC6A13	ADAMTS13	0.013106	Co-expression	Dobbin-Giordano-2005
AP4E1	ADAMTS13	0.024775	Co-expression	Dobbin-Giordano-2005
AOC2	GK2	0.018189	Co-expression	Dobbin-Giordano-2005
ANGPTL6	ADAMTS13	0.030756	Co-expression	Innocenti-Brown-2011
TRPV1	ADAMTS13	0.012766	Co-expression	Innocenti-Brown-2011
KCNK17	ADAMTS13	0.025007	Co-expression	Innocenti-Brown-2011
POFUT2	ADAMTS10	0.011832	Co-expression	Noble-Diehl-2008
AOC2	ADAMTS13	0.014705	Co-expression	Noble-Diehl-2008
ADAMTS7	ADAMTS13	0.025154	Co-expression	Smirnov-Cheung-2009
GK2	ADAMTS13	0.019954	Co-expression	Smirnov-Cheung-2009
SLC6A9	ADAMTS13	0.022157	Co-expression	Smirnov-Cheung-2009
SLC6A13	ADAMTS13	0.016187	Co-expression	Smirnov-Cheung-2009
CLDN6	ADAMTS13	0.020231	Co-expression	Smirnov-Cheung-2009
ADAMTS7	ADAMTS13	0.011667	Co-expression	Wang-Cheung-2015
TAS2R7	ADAMTS13	0.011175	Co-expression	Wang-Cheung-2015
SLC6A9	ADAMTS13	0.012103	Co-expression	Wang-Cheung-2015
AOC2	ADAMTS13	0.016991	Co-expression	Wang-Cheung-2015
CLDN6	ADAMTS13	0.010212	Co-expression	Wang-Cheung-2015
CACNG4	ADAMTS13	0.023497	Co-expression	Chen-Brown-2002
ADAMTS10	ADAMTS13	0.022796	Co-expression	Chen-Brown-2002
AP4E1	ADAMTS10	0.016491	Co-expression	Chen-Brown-2002
SLC6A13	SLC6A9	0.003413	Co-expression	Wu-Garvey-2007
F8	VWF	0.060129	Pathway	Wu-Stein-2010
F8	VWF	0.294935	Pathway	REACTOME
VWF	ADAMTS13	0.55051	Physical Interactions	IREF-DIP
F8	ADAMTS13	0.387079	Physical Interactions	IREF-DIP
F8	VWF	0.387079	Physical Interactions	IREF-DIP
F8	VWF	0.185599	Physical Interactions	BIOGRID-SMALL-SCALE-STUDIES
VWF	ADAMTS13	0.72218	Physical Interactions	IREF-INTACT
VWF	ADAMTS13	0.586387	Physical Interactions	IREF-HPRD
F8	VWF	0.081584	Physical Interactions	IREF-HPRD
VWF	ADAMTS13	0.692532	Predicted	Wu-Stein-2010
ADAMTS7	ADAMTS13	0.01789	Shared protein domains	INTERPRO
ADAMTS10	ADAMTS13	0.017896	Shared protein domains	INTERPRO
ADAMTS10	ADAMTS7	0.0318	Shared protein domains	INTERPRO
ADAMTS6	ADAMTS13	0.017888	Shared protein domains	INTERPRO
ADAMTS6	ADAMTS7	0.031785	Shared protein domains	INTERPRO
ADAMTS6	ADAMTS10	0.031796	Shared protein domains	INTERPRO
SLC6A13	SLC6A9	0.054687	Shared protein domains	INTERPRO
CLDN6	CACNG4	0.015305	Shared protein domains	INTERPRO
ADAMTS7	ADAMTS13	0.020768	Shared protein domains	PFAM
ADAMTS10	ADAMTS13	0.018679	Shared protein domains	PFAM
ADAMTS10	ADAMTS7	0.025162	Shared protein domains	PFAM
ADAMTS6	ADAMTS13	0.018676	Shared protein domains	PFAM

ADAMTS6	ADAMTS7	0.025158	Shared protein domains	PFAM
ADAMTS6	ADAMTS10	0.030488	Shared protein domains	PFAM
SLC6A13	SLC6A9	0.052632	Shared protein domains	PFAM
CLDN6	CACNG4	0.022244	Shared protein domains	PFAM

Figure (52): Interaction between *ADAMTS13* and its related genes

Novel deleterious SNPs in *ADAMTS13* gene revealed by this study:

Table (6): Novel deleterious mutations in *ADAMTS13* gene

NO	Amino Acid Change	NO	Amino Acid Change	NO	Amino Acid Change	NO	Amino Acid Change	NO	Amino Acid Change
1	S207R	2	C208S	3	G215S	4	S263Y	5	P301R
6	G302A	7	L335P	8	G403V	9	C411Y	10	P416H
11	G419W	12	G419A	13	G419V	14	C423R	15	G425D
16	G425V	17	C450R	18	C483Y	19	D504N	20	T506N
21	R660W	22	S696W	23	C699R	24	C758W	25	G759R
26	G759W	27	C864R	28	G911V	29	R979W	30	C1028R
31	C1028Y	32	G1031R	33	R1035C	34	C1039Y	35	C1192Y

DISCUSSION

Our in-depth analysis of the SNPs in the *ADAMTS13* gene found 51 amino acid changes that are highly pathogenic according to our insilico analysis. According to the dbSNP database some of these SNPs are listed as per their clinical impact as benign, pathogenic, and untested or no information is available. One of the aims of our study is to confirm or refute these claims based on computational analysis. 35 deleterious SNPs, not previously mentioned in the literature, were determined to be novel mutations and are listed in Table (6).

R398H, C508Y, C951G, C1024G are listed as being pathogenic by dbSNP. Several studies [14, 21, 22, 36-38] have found R398H mutation to be detrimental. Similarly, wet lab studies confirmed the pathogenicity of C508Y[21], C951G and C1024G[36] mutations. H234Q, D235Y, C311Y, P353L, W390C, G525D and C908Y are categorized as 'untested' in dbSNP. H234Q mutation in the *ADAMTS13* gene found to be damaging through insilico methods in this study was also found to be the cause of repeated renal failure in an adult patient [39]. D235Y mutation has also been studied in patients with congenital TTP [40]. Similarly, C311Y and P353L mutations in the *ADAMTS13* gene have been found in patients with congenital TTP in more than one study[14, 37]. W390C mutation has been implicated in TTP and HUM (hemolytic uremic syndrome) [5]. G525D and C908Y *ADAMTS13* mutations were found in Japanese patients with Upshaw-Shulman syndrome [2]. No clinical information was provided by dbSNP for the following mutations: R398C, R409W, R421C, G761S and C908S. However, several studies have indeed been conducted. A paper published in 2012 studied congenital TTP patients in the UK and confirmed the pathogenicity of R398C and R409W mutations and their impact on *ADAMTS13* activity [22]. Sequencing of the *ADAMTS* gene in patients with deep vein thrombosis identified R421C mutation [41]. G761S mutation was identified in patients with impaired renal function [40], while C908S mutation was one of 10 *ADAMTS13* gene mutations in six families with congenital TTP [38].

CONCLUSION

According to our analysis, we found 35 nsSNPs effects on *ADAMTS13* protein leading to thrombotic thrombocytopenic purpura using computational approach. Bioinformatics tools are vital in prediction analysis, making use of increasingly voluminous biomedical data thereby providing markers for screening or for genetic mapping studies.

ACKNOWLEDGMENT

The authors wish to acknowledge the enthusiastic cooperation of Africa City of Technology - Sudan.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this paper.

DATA AVAILABILITY

All relevant data used to support the findings of this study are included within the manuscript and supplementary information files.

REFERENCES

1. Dong, J.F., et al., *ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions*. *Blood*, 2002. **100**(12): p. 4033-9.
2. Fujimura, Y., et al., *Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan*. *J Thromb Haemost*, 2011. **9 Suppl 1**: p. 283-301.
3. Schneppenheim, R., et al., *Severe ADAMTS-13 deficiency in childhood*. *Semin Hematol*, 2004. **41**(1): p. 83-9.
4. Joly, B.S., P. Coppo, and A. Veyradier, *Thrombotic thrombocytopenic purpura*. *Blood*, 2017. **129**(21): p. 2836-2846.
5. Licht, C., et al., *Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS)*. *Kidney Int*, 2004. **66**(3): p. 955-8.
6. Schneppenheim, R., et al., *von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP*. *Blood*, 2003. **101**(5): p. 1845-50.
7. de Groot, R., et al., *Essential role of the disintegrin-like domain in ADAMTS13 function*. *Blood*, 2009. **113**(22): p. 5609-16.
8. Zheng, X.L., *Structure-function and regulation of ADAMTS-13 protease*. *J Thromb Haemost*, 2013. **11 Suppl 1**: p. 11-23.
9. Ling, J., et al., *The WXXW motif in the TSR1 of ADAMTS13 is important for its secretion and proteolytic activity*. *Thromb Res*, 2013. **131**(6): p. 529-34.
10. Levy, G.G., et al., *Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura*. *Nature*, 2001. **413**(6855): p. 488-94.
11. Manea, M. and D. Karpman, *Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura*. *Pediatr Nephrol*, 2009. **24**(3): p. 447-58.
12. Manea, M., et al., *Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura*. *Br J Haematol*, 2007. **138**(5): p. 651-62.
13. Bramham, K., et al., *ADAMTS-13 deficiency: can it cause chronic renal failure?* *Nephrol Dial Transplant*, 2011. **26**(2): p. 742-4.
14. Assink, K., et al., *Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency*. *Kidney Int*, 2003. **63**(6): p. 1995-9.
15. Joly, B.S., P. Coppo, and A. Veyradier, *Pediatric thrombotic thrombocytopenic purpura*. *Eur J Haematol*, 2018. **101**(4): p. 425-434.
16. Sadler, J.E., et al., *Recent advances in thrombotic thrombocytopenic purpura*. *Hematology Am Soc Hematol Educ Program*, 2004: p. 407-23.
17. Tao, Z., et al., *Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow*. *Blood*, 2005. **106**(1): p. 141-3.
18. Kokame, K. and T. Miyata, *Genetic defects leading to hereditary thrombotic thrombocytopenic purpura*. *Semin Hematol*, 2004. **41**(1): p. 34-40.
19. Kokame, K., et al., *Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome*. *J Thromb Haemost*, 2008. **6**(1): p. 213-5.
20. Peyvandi, F., et al., *Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity*. *Hum Mutat*, 2006. **27**(4): p. 330-6.
21. Kokame, K., et al., *Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity*. *Proc Natl Acad Sci U S A*, 2002. **99**(18): p. 11902-7.
22. Camilleri, R.S., et al., *A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom*. *J Thromb Haemost*, 2012. **10**(9): p. 1792-801.
23. Lotta, L.A., et al., *Residual plasmatc activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura*. *Blood*, 2012. **120**(2): p. 440-8.

24. Benson, D.A., et al., *GenBank*. Nucleic Acids Res, 2012. **40**(Database issue): p. D48-53.
25. Artimo, P., et al., *ExPASy: SIB bioinformatics resource portal*. Nucleic Acids Res, 2012. **40**(Web Server issue): p. W597-603.
26. Sim, N.L., et al., *SIFT web server: predicting effects of amino acid substitutions on proteins*. Nucleic Acids Res, 2012. **40**(Web Server issue): p. W452-7.
27. Adzhubei, I.A., et al., *A method and server for predicting damaging missense mutations*. Nat Methods, 2010. **7**(4): p. 248-9.
28. Choi, Y., et al., *Predicting the functional effect of amino acid substitutions and indels*. PLoS One, 2012. **7**(10): p. e46688.
29. Hecht, M., Y. Bromberg, and B. Rost, *Better prediction of functional effects for sequence variants*. BMC Genomics, 2015. **16 Suppl 8**: p. S1.
30. Calabrese, R., et al., *Functional annotations improve the predictive score of human disease-related mutations in proteins*. Hum Mutat, 2009. **30**(8): p. 1237-44.
31. Lopez-Ferrando, V., et al., *PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update*. Nucleic Acids Res, 2017. **45**(W1): p. W222-W228.
32. Capriotti, E., P. Fariselli, and R. Casadio, *I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure*. Nucleic Acids Res, 2005. **33**(Web Server issue): p. W306-10.
33. Venselaar, H., et al., *Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces*. BMC Bioinformatics, 2010. **11**: p. 548.
34. Pettersen, E.F., et al., *UCSF Chimera--a visualization system for exploratory research and analysis*. J Comput Chem, 2004. **25**(13): p. 1605-12.
35. Warde-Farley, D., et al., *The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function*. Nucleic Acids Res, 2010. **38**(Web Server issue): p. W214-20.
36. Shelat, S.G., J. Ai, and X.L. Zheng, *Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays*. Semin Thromb Hemost, 2005. **31**(6): p. 659-72.
37. Hing, Z.A., et al., *Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura*. Br J Haematol, 2013. **160**(6): p. 825-37.
38. Veyradier, A., et al., *Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome)*. J Thromb Haemost, 2004. **2**(3): p. 424-9.
39. Shibagaki, Y., et al., *Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure*. Nephrol Dial Transplant, 2006. **21**(5): p. 1289-92.
40. Rurali, E., et al., *ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment*. Clin J Am Soc Nephrol, 2015. **10**(11): p. 2002-12.
41. Pagliari, M.T., et al., *Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis*. PLoS One, 2016. **11**(11): p. e0165665.